Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review. Issue 6 (August 2019)

• Record Type: Journal Article
• Authors: Vannappagari, Vani; Ragone, Leigh; Henegar, Cassidy; van Wyk, Jean; Brown, Dannae; Demarest, James; Quercia, Romina; Clair, Marty St.; Underwood, Mark; Gatell, Jose M; de Ruiter, Annemiek; Aboud, Michael
• Is Part Of: Antiviral therapy. Volume 24:Issue 6(2019)
• Page Start: 393
• Page End: 404
• Publication Date: 2019-08
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3331
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: Pretreatment and acquired drug resistance mutations (DRMs) can limit antiretroviral therapy effectiveness. Methods: We review prevalence of DRMs with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), focusing on lamivudine and rilpivirine, from 127 articles with >100, 000 individuals with HIV-1 infection. Results: Estimated global prevalence of pretreatment resistance to any NRTI was 4% and to any NNRTI was 6%. Most prevalent DRMs resistant to lamivudine or rilpivirine were at positions E138 (4%), V179 (1%) and M184 (1%). Estimated acquired DRM prevalence was 58% for any NRTIs and 67% for any NNRTIs, most frequently at positions M184 (58%) and Y181 (21%). Conclusions: This review suggests low risk of lamivudine-or rilpivirine-resistant mutations in treatment-naive, HIV-1-infected individuals.